ACTEMRA INJECTION 162MG

Actemra 162mg injection contains an active ingredient known as tocilizumab. This medication is classified as a monoclonal antibody, which is a protein derived from specific immune cells. It is utilized for conditions such as moderate to severe active rheumatoid arthritis (RA) in patients who have not responded adequately to other rheumatoid treatments, giant cell arteritis (a disease affecting the arteries), and in children with systemic juvenile idiopathic arthritis (sJIA) or polyarticular juvenile idiopathic arthritis (pJIA), which can cause pain and swelling in one or more joints in children aged 1 to 2 years and older.

Children who experience allergic reactions to Actemra injection or its components, as well as those with severe infections, should seek advice from their doctor prior to using this medication. It is crucial to contact your doctor immediately if you experience any allergic reactions (such as difficulty breathing, chest tightness, rash, itching, hives, or swelling of the lips, tongue, or face), infections (whether short-term or long-term), tuberculosis, intestinal ulcers, or diverticulitis (the formation of small bulging pouches in the digestive tract), liver disease, cancer, kidney function issues, or persistent headaches.

Notify your doctor if the child has a history of macrophage activation syndrome (the activation and uncontrolled proliferation of specific blood cells). Older adults are at a higher risk of developing infections compared to the general population, making it essential to exercise caution when treating them. Consult your doctor if you are planning to become pregnant, suspect you may be pregnant, or are currently breastfeeding.